CAL 130 manufacturers
- CAL-130
-
- $1520.00
-
2026-07-27
- CAS:1431697-74-3
- Purity:
- Supply Ability: 10g
- CAL-130
-
- $1520.00
-
2026-07-27
- CAS:1431697-74-3
- Purity:
- Supply Ability: 10g
- CAL-130
-
- $1980.00
-
2025-08-22
- CAS:1431697-74-3
- Purity:
- Supply Ability: 10g
|
| | CAL 130 Basic information |
| Product Name: | CAL 130 | | Synonyms: | CAL130; CAL 130;4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-9H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)-;2-?[(1S)?-?1-?[(2-?Amino-?9H-?purin-?6-?yl)?amino]?ethyl]?-?5-?methyl-?3-?(2-?methylphenyl)?-4(3H)?-?quinazolinone | | CAS: | 1431697-74-3 | | MF: | C23H22N8O | | MW: | 426.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1431697-74-3.mol |  |
| | CAL 130 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO | | form | Powder |
| | CAL 130 Usage And Synthesis |
| Uses | CAL-130 is a PI3Kδ and PI3Kγ inhibitor with IC50s of 1.3 and 6.1 nM, respectively. | | in vivo | The clinical significance of interfering with the combined activities of PI3Kγ and PI3Kδ is determined by administering CAL-130 to Lck/Ptenfl/fl mice with established T cell acute lymphoblastic leukemia (T-ALL). Candidate animals for survival studies are ill appearing, have a white blood cell (WBC) count above 45,000 μL-1, evidence of blasts on peripheral smear, and a majority of circulation cells (>75%) staining double positive for Thy1.2 and Ki-67. Mice receive an oral dose (10 mg/kg) of CAL-130 every 8 hr for a period of 7 days and are then followed until moribund. Despite the limited duration of therapy, CAL-130 is highly effective in extending the median survival for treated animals to 45 days as compared 7.5 days for the control group[1]. | | IC 50 | p110δ: 1.3 nM (IC50); p110γ: 6.1 nM (IC50); p110β: 56 nM (IC50); p110α: 115 nM (IC50) | | References | [1] Subramaniam Prem S, et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer cell (2012), 21(4), 459-72. DOI:10.1016/j.ccr.2012.02.029 |
| | CAL 130 Preparation Products And Raw materials |
|